RELMADA THERAPEUTICS, INC. (RLMD)
SEC fundamentals · as filed in 10-Q FY2026, period ended Jun 30, 2026 · updated Oct 23, 2026
as filed in 10-Q FY2026, period ended Jun 30, 2026 · View filings on EDGAR ↗
In its 10-Q for the period ended Jun 30, 2026, RELMADA THERAPEUTICS, INC. reported net income of -$12.9M and total assets of $219.1M. Every figure below is taken directly from RELMADA THERAPEUTICS, INC.'s SEC filings: each links to the source document on EDGAR.
Revenue and net income by fiscal year
As reported in each year’s annual filing · USD
| Fiscal year | Revenue | Net income |
|---|---|---|
| FY2025 | — | -$57.4M |
| FY2024 | — | -$80.0M |
| FY2023 | — | -$98.8M |
| FY2022 | — | -$157.0M |
| FY2021 | — | -$125.8M |
| FY2020 | — | -$59.5M |
| FY2019 | — | -$15.0M |
| FY2018 | — | -$9.0M |
| FY2017 | — | -$6.3M |
| FY2016 | — | -$3.0M |
Recent SEC filings
Filed by the registrant · newest first · insider forms and holder schedules not included
| Form | Filed | Source |
|---|---|---|
| 8-K | Sep 8, 2026 | on EDGAR ↗ |
| 8-K | Aug 6, 2026 | on EDGAR ↗ |
| 10-Q | Aug 6, 2026 | on EDGAR ↗ |
| 8-K | Jul 28, 2026 | on EDGAR ↗ |
| 8-K | May 28, 2026 | on EDGAR ↗ |
| 10-Q | May 12, 2026 | on EDGAR ↗ |
| 8-K | May 12, 2026 | on EDGAR ↗ |
| DEF 14A | Apr 17, 2026 | on EDGAR ↗ |
| 8-K | Mar 20, 2026 | on EDGAR ↗ |
| 10-K | Mar 19, 2026 | on EDGAR ↗ |
Balance Sheet
as of Jun 30, 2026 · 10-Q
Income Statement
10-Q (quarterly) · period ended Jun 30, 2026
Per Share & Cash Flow
10-Q (quarterly) · period ended Jun 30, 2026
| EPS (diluted) | $-0.11 | Earnings | source ↗ |
| EPS (basic) | $-0.11 | Earnings | source ↗ |
| Shares Outstanding | 106.7M | Entity | source ↗ |
| Cash from Operations | -$9.6M | Net | source ↗ |
| Cash from Financing | -$6.4M | Net | source ↗ |
| Cash from Investing | $17.6M | Net | source ↗ |
Insider activity
Form 4 open-market activity, last 180 days
- Buys
- 4
- Sells
- 0
- Net shares
- +400.0K
Restatement history
Point-in-time1 of 304 annual fact-keys were materially restated between filings: what RELMADA THERAPEUTICS, INC. first reported differed from what it later filed. We keep every vintage of every annual figure, each keyed to its EDGAR accession.
See each original-vs-restated value, and query any company as of any past date, with the point-in-time API.
Deeper fundamentals
A free API key reaches RLMD’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.
Programmatic access
Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.
- These fundamentals, as filed
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/RLMD
MCP tool:
get_sec_fundamentals ticker=RLMD - The same figures as they were known on any past date
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/RLMD/as-of/YYYY-MM-DD
MCP tool:
get_asof_fundamentals ticker=RLMD as_of=YYYY-MM-DD - Fiscal-year trajectory: revenue, margins, free cash flow
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/RLMD/history
MCP tool:
get_fundamentals_history ticker=RLMD - Leverage, liquidity, margin and return ratios
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/financial-health/RLMD
MCP tool:
get_financial_health ticker=RLMD
Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.